HC Wainwright Analysts Lift Earnings Estimates for OBIO

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Orchestra BioMed to ($0.39) per share, improving from a previous forecast of ($0.52), indicating anticipated better performance.
• The current consensus target price for Orchestra BioMed's stock is $13.50, with investment analysts generally maintaining a "Buy" rating.
• Insider activity includes a purchase of 20,000 shares by David P. Hochman at $2.75 per share, reflecting a strong belief in the company's potential growth.

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Orchestra BioMed in a note issued to investors on Thursday, September 4th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.52). HC Wainwright currently has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Orchestra BioMed's current full-year earnings is ($1.66) per share. HC Wainwright also issued estimates for Orchestra BioMed's Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.34) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.34) EPS and FY2026 earnings at ($1.37) EPS.

Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.01. Orchestra BioMed had a negative net margin of 2,367.49% and a negative return on equity of 289.42%. The firm had revenue of $0.84 million during the quarter, compared to the consensus estimate of $0.78 million.

Other analysts also recently issued research reports about the stock. Chardan Capital reissued a "buy" rating and issued a $20.00 price objective on shares of Orchestra BioMed in a research note on Wednesday, August 13th. BTIG Research reaffirmed a "neutral" rating on shares of Orchestra BioMed in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $13.50.

Orchestra BioMed Trading Down 1.9%

Shares of NASDAQ:OBIO traded down $0.05 during trading on Monday, reaching $2.57. The company's stock had a trading volume of 119,272 shares, compared to its average volume of 257,508. The company has a current ratio of 2.10, a quick ratio of 2.09 and a debt-to-equity ratio of 48.76. The stock has a market capitalization of $99.30 million, a PE ratio of -1.40 and a beta of 0.61. Orchestra BioMed has a 12 month low of $2.37 and a 12 month high of $6.50. The firm's 50 day simple moving average is $2.82 and its two-hundred day simple moving average is $3.11.

Insider Transactions at Orchestra BioMed

In other Orchestra BioMed news, insider David P. Hochman bought 20,000 shares of the firm's stock in a transaction that occurred on Monday, August 4th. The stock was bought at an average cost of $2.75 per share, for a total transaction of $55,000.00. Following the completion of the transaction, the insider directly owned 349,331 shares of the company's stock, valued at approximately $960,660.25. This trade represents a 6.07% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have acquired 36,760 shares of company stock worth $97,934 in the last three months. Insiders own 8.10% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in OBIO. Wells Fargo & Company MN increased its stake in shares of Orchestra BioMed by 43.6% during the fourth quarter. Wells Fargo & Company MN now owns 13,156 shares of the company's stock worth $53,000 after purchasing an additional 3,992 shares in the last quarter. Barclays PLC grew its stake in Orchestra BioMed by 18.9% during the 4th quarter. Barclays PLC now owns 37,786 shares of the company's stock valued at $152,000 after acquiring an additional 6,001 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in Orchestra BioMed by 11.1% during the 4th quarter. The Manufacturers Life Insurance Company now owns 37,009 shares of the company's stock valued at $148,000 after acquiring an additional 3,704 shares in the last quarter. Northern Trust Corp grew its stake in Orchestra BioMed by 2.5% during the 4th quarter. Northern Trust Corp now owns 236,761 shares of the company's stock valued at $947,000 after acquiring an additional 5,725 shares in the last quarter. Finally, Bank of America Corp DE grew its stake in Orchestra BioMed by 42.0% during the 4th quarter. Bank of America Corp DE now owns 23,780 shares of the company's stock valued at $95,000 after acquiring an additional 7,036 shares in the last quarter. 53.20% of the stock is currently owned by institutional investors and hedge funds.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.